Stephen Marder

Image of Stephen Marder

Stephen R. Marder, M.D. received his A.B. from the University of Pennsylvania and his M.D. from the State University of New York at Buffalo. After an internship at Denver General Hospital he completed a residency at the University of Southern California. From 1975 to 1977 he was a Clinical Associate in the Biological Psychiatry Branch at the National Institute of Mental Health. In 1977 he joined the staff at the Brentwood VA Medical Center and the faculty at UCLA. Dr. Marder's research has focused on the drug treatment of schizophrenia and the pharmacology of antipsychotic drugs. He has authored or co-authored more than 200 journal articles and chapters based on research. The Schizophrenia Research Unit that he developed together with the late Theodore Van Putten has been an important site for training a number of psychiatrists who developed careers in research. He has been a Professor and Vice Chair of the Department of Psychiatry at UCLA since 1991. He is currently the Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs and the Director of the Section on Psychosis at the UCLA Neuropsychiatric Institute.


Contact information


Mailing Address:
UCLA Psychr & Biobehav Sci / VA Greater LA Healthcare Sys
BOX 951667, 11301 Wilshire Blvd. MIRECC Bldg 210, Rm 130
Los Angeles, CA 90073
UNITED STATES


Email: marder@ucla.edu

Publications

Kern Robert S, Glynn Shirley M, Horan William P, Marder Stephen R Psychosocial treatments to promote functional recovery in schizophrenia.. Schizophrenia bulletin. 2009; 35(2): 347-61.
Zhu Baojin, Ascher-Svanum Haya, Shi Lizheng, Faries Douglas, Montgomery William, Marder Stephen R Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.. Psychiatric services (Washington, D.C.). 2008; 59(3): 315-7.
Green Michael F, Nuechterlein Keith H, Kern Robert S, Baade Lyle E, Fenton Wayne S, Gold James M, Keefe Richard S E, Mesholam-Gately Raquelle, Seidman Larry J, Stover Ellen, Marder Stephen R Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.. The American journal of psychiatry. 2008; 165(2): 221-8.
Stover Ellen L, Brady Linda, Marder Stephen R New paradigms for treatment development.. Schizophrenia bulletin. 2007; 33(5): 1093-9.
Shi Lizheng, Ascher-Svanum Haya, Zhu Baojin, Faries Douglas, Montgomery William, Marder Stephen R Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.. Psychiatric services (Washington, D.C.). 2007; 58(4): 482-8.
Kirkpatrick Brian, Fenton Wayne S, Carpenter William T, Marder Stephen R The NIMH-MATRICS consensus statement on negative symptoms.. Schizophrenia bulletin. 2006; 32(2): 214-9.
Marder Stephen R, Fenton Wayne Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.. Schizophrenia research. 2004; 72(1): 5-9.
Marder Stephen R, Essock Susan M, Miller Alexander L, Buchanan Robert W, Casey Daniel E, Davis John M, Kane John M, Lieberman Jeffrey A, Schooler Nina R, Covell Nancy, Stroup Scott, Weissman Ellen M, Wirshing Donna A, Hall Catherine S, Pogach Leonard, Pi-Sunyer Xavier, Bigger J Thomas, Friedman Alan, Kleinberg David, Yevich Steven J, Davis Bonnie, Shon Steven Physical health monitoring of patients with schizophrenia.. The American journal of psychiatry. 2004; 161(8): 1334-49.
Marder Stephen R, Glynn Shirley M, Wirshing William C, Wirshing Donna A, Ross Doreen, Widmark Clifford, Mintz Jim, Liberman Robert P, Blair Karen E Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.. The American journal of psychiatry. 2003; 160(8): 1405-12.
  • Printer-friendly version
  • share

Centers, Programs, Divisions and other groups